ACZONE 7.5% Rx
Generic Name and Formulations:
Dapsone 7.5%; gel.
Indications for ACZONE 7.5%:
Wash skin and pat dry. Apply pea-sized amount to entire face or other affected area in a thin layer once daily. Rub in gently and completely. Wash hands after use. Reevaluate if no improvement after 12 weeks.
Avoid in congenital or idiopathic methemoglobinemia. G6PD deficiency: may have increased risk of methemoglobinemia or hemolytic anemia; discontinue if occurs. Pregnancy. Nursing mothers.
Increased risk of hemolysis in G6PD-deficient patients with concomitant trimethoprim/sulfamethoxazole, other folic acid antagonists (eg, pyrimethamine), anticonvulsants, rifampin, St. John's wort. Increased risk of methemoglobinemia with concomitant sulfonamides, acetaminophen, chloroquine, nitrates, nitrites, nitrofurantoin, phenobarbital, phenytoin, primaquine, quinine, and others. Skin/hair discoloration with topical benzoyl peroxide.
Application site reactions (oiliness, peeling, dryness, erythema, pruritus).
Gel 5% (tubes)—30g, 60g, 90g; Gel 7.5% (pumps)—30g, 60g, 90g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC